These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11269048)

  • 1. [Autoimmune lymphoproliferative syndrome(ALPS)].
    Kasahara Y
    Ryoikibetsu Shokogun Shirizu; 2000; (31):168-71. PubMed ID: 11269048
    [No Abstract]   [Full Text] [Related]  

  • 2. Inherited and acquired death receptor defects in human Autoimmune Lymphoproliferative Syndrome.
    Rieux-Laucat F
    Curr Dir Autoimmun; 2006; 9():18-36. PubMed ID: 16394653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.
    Siegel RM; Chan FK; Chun HJ; Lenardo MJ
    Nat Immunol; 2000 Dec; 1(6):469-74. PubMed ID: 11101867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical role of the Fas/Fas ligand system].
    Droździk M; Białecka M
    Pol Arch Med Wewn; 1999 Apr; 101(4):337-43. PubMed ID: 10740413
    [No Abstract]   [Full Text] [Related]  

  • 5. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Puck JM; Sneller MC
    Semin Immunol; 1997 Feb; 9(1):77-84. PubMed ID: 9106310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune lymphoproliferative syndrome: types I, II and beyond.
    Chun HJ; Lenardo MJ
    Adv Exp Med Biol; 2001; 490():49-57. PubMed ID: 11505974
    [No Abstract]   [Full Text] [Related]  

  • 7. Impaired apoptosis of lymphocytes derived from patient with decreased expression of caspase-8 results in Alps-like phenotype.
    Grzela T; Krauze A; Grzela K; Lazarczyk M; Niderla J; Brawura-Biskupski-Samaha R; Dziunycz P; Milewski L; Korczak-Kowalska G; Kulus M
    Int J Mol Med; 2004 Nov; 14(5):937-42. PubMed ID: 15492869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
    Fuchs H; Posovszky C; Lahr G; van der Werff ten Bosch J; Boehler T; Debatin KM
    Pediatr Res; 2009 Feb; 65(2):163-8. PubMed ID: 18948840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.
    Wang J; Zheng L; Lobito A; Chan FK; Dale J; Sneller M; Yao X; Puck JM; Straus SE; Lenardo MJ
    Cell; 1999 Jul; 98(1):47-58. PubMed ID: 10412980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis.
    Fleisher TA
    Immunol Res; 2008; 40(1):87-92. PubMed ID: 18193364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune lymphoproliferative syndrome with somatic Fas mutations.
    Holzelova E; Vonarbourg C; Stolzenberg MC; Arkwright PD; Selz F; Prieur AM; Blanche S; Bartunkova J; Vilmer E; Fischer A; Le Deist F; Rieux-Laucat F
    N Engl J Med; 2004 Sep; 351(14):1409-18. PubMed ID: 15459302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.
    Jackson CE; Puck JM
    Curr Opin Pediatr; 1999 Dec; 11(6):521-7. PubMed ID: 10590910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new peak in the ALPS.
    Fischer A; Rieux-Laucat F; Le Deist F
    Nat Med; 1999 Aug; 5(8):876-7. PubMed ID: 10426307
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of proapoptotic activity of soluble CD95 ligand is due to its failure to induce CD95 oligomers.
    Jang S; Krammer PH; Salgame P
    J Interferon Cytokine Res; 2003 Aug; 23(8):441-7. PubMed ID: 13678432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation.
    Belka C; Marini P; Lepple-Wienhues A; Budach W; Jekle A; Los M; Lang F; Schulze-Osthoff K; Gulbins E; Bamberg M
    Oncogene; 1999 Sep; 18(35):4983-92. PubMed ID: 10490833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
    Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
    Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.
    Worth A; Thrasher AJ; Gaspar HB
    Br J Haematol; 2006 Apr; 133(2):124-40. PubMed ID: 16611303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune lymphoproliferative syndrome type III, an indefinite disorder.
    van der Werff ten Bosch J; Otten J; Thielemans K
    Leuk Lymphoma; 2001 May; 41(5-6):501-11. PubMed ID: 11378568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.